October 25, 2011
Finkelstein Thompson LLP Announces An Investigation Involving Complications from Actos.
Finkelstein Thompson LLP is investigating reports of reports of alleged complications associated with Actos. Actos is prescribed for the treatment of persons with Type-2 diabetes. The drug Actos has been under investigation from a variety of sources as a possible cause of bladder cancer. Recent studies indicate that Actos users may have an increased risk of bladder cancer the longer the medication is taken.
The U.S. Food and Drug Administration (FDA) issued a safety announcement June 15, 2011 that there may be a connection between using Actos for more than one year and a risk of bladder cancer. France conducted a 3-year study of the drug and, as a result of its findings on Actos' side effects, the country banned the drug on June 10, 2011. Germany followed suit after looking over the French data and also banned Actos. The FDA said it is reviewing the results of the French research.